RE: AGM reviewMugen I agree that Rosconi and Pommier weren't too impressed with the question asked by that obvious distraught shareholder. I wanted to ask a similar question since its been burning me since January why they announced Strategic Review + PP in the same PR, but didn't get a chance. This was my first AGM for TH, so was just feeling out the room. I say Rosconi at Biocontact 07, and its seems people are certainly more bold to ask questions then...
Simon, I think they are holding back on public announcement of the second indication so they can get the best price for the first indication. Strategically, if they need to announce it to get more money on the table I think they will, but if the second indication is obesity, I don't see how it will add more value to the first, it may actually take some away. The reason being that a potential suitor may be banking on targeting obesity through off-label use, so the value to them shrinks if TH decides to pursue this on the second indication...
For the last year TH has been talking about the potential of this drug, and its numerous possible indications. I do not think they would want to sell its potential short but selling the company before we know exactly how much this is worth. I think they are picking their fights. Once HIV indication is approved, then the other indications will be easier since less trials required and the post-market studies from the HIV indication lend more leverage to the safety argument...if they sold the drug outright, I can see where they would still want multiples of the current SP.
If anyone is in communications with Rosconi, Gilepen or anyone else from TH, it'd be nice to know if my little fantasy scenario has some truth in it.
IFC
P.S. And no Simon, I didn't ask any questions, so it seems everyone on the board remains faceless for now...at the next meeting I'll look for the guy vigorous taking notes;)...BTW, are you still following NRM?---I haven't gone to that board in a while.